Código QR (código de barras bidimensional)

Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis

BackgroundThe combination of cyclin-dependent kinases 4/6 (CDK4/6) inhibitors and endocrine therapy is the standard treatment for patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer. However, the role of CDK4/6 inhibitors in early breast cancer remains controve...

תיאור מלא

שמור ב:
Principais autores: Zhihao Zhang, Xin Zhao, Jie Chen
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2024-09-01
סדרה:Frontiers in Pharmacology
נושאים:
CDK4/6 inhibitors
HR-positive
adjuvant
breast cancer
endocrine therapy
גישה מקוונת:https://www.frontiersin.org/articles/10.3389/fphar.2024.1438288/full
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים